Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

12 Jul 2013

Abstract excerpt

RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas. Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical trials. Here we evaluated lenvatinib in RET gene fusion-driven preclinical models. In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET. Lenvatinib suppressed the growth of CCDC6-RET human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23856031
DOI: 10.1016/j.canlet.2013.07.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsPMID 23856031Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Semantic proximity Read ↗

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.Semantic proximity Read ↗

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Semantic proximity Read ↗

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsSemantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read ↗

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.Semantic proximity Read ↗

REToma: a cancer subtype with a shared driver oncogene.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.